Quality Use of Respiratory Medicines, Clinical Management, Woolcock Institute of Medical Research, Glebe, Australia.
School of Medicine and Health, The University of Sydney, Sydney, Australia.
J Asthma. 2022 Jan;59(1):178-188. doi: 10.1080/02770903.2020.1841223. Epub 2020 Nov 3.
High use of short-acting beta-2-agonist (SABA) medication is a significant problem. Attitudes and perceptions toward asthma of over-the-counter (OTC) reliever users are unknown. The study aimed to describe the asthma attitudes, perceptions, medication knowledge and information gathering behavior of people with asthma with recent high SABA use (i.e. SABA use > twice a week in the last 4 weeks) and compare them to people with asthma with no recent high SABA use.
A real-world cross-sectional observational study in Australian community pharmacies was conducted; surveying patients ages ≥ 16 years requesting SABA medication OTC. Data collected included; demographics, medication usage, asthma control, asthma-related perceptions and behaviors. Data were summarized by using descriptive analyses.
375 participants completed the survey, 73.9% were high SABA users. Of the 375, 90.4% reported that their asthma symptoms were controlled or somewhat controlled and 56.0% felt that their asthma was not serious. However, only 17.6%, had controlled asthma according to GINA-defined criteria. High SABA users tended to be more anxious about their asthma and worried about its impact in the future (50.5% vs. 28.6%, < 0.001). High SABA users were more likely to agree with the statements suggesting that asthma impacted on activities of daily living (46.6% vs. 16.3%, < 0.001); were socially conscious about their asthma and more likely to feel embarrassed carrying (21.3% vs 9.2%, = 0.007) and using (29.2% vs 18.4%, = 0.036) their asthma inhaler.
This study revealed the extent of uncontrolled asthma and uncovered an anxious and socially conscious group of OTC SABA users. There is a need to better understand patient perceptions and their relationships to high-SABA use, to ensure targeted educational interventions are developed and implemented.
高频率使用短效 β2-受体激动剂(SABA)药物是一个重大问题。目前尚不清楚非处方(OTC)缓解药物使用者对哮喘的态度和看法。本研究旨在描述近期高 SABA 使用(即过去 4 周内每周使用 SABA 超过 2 次)的哮喘患者的哮喘态度、认知、药物知识和信息收集行为,并将其与近期无高 SABA 使用的哮喘患者进行比较。
在澳大利亚社区药房进行了一项真实世界的横断面观察性研究;调查了年龄≥16 岁、要求 OTC 使用 SABA 药物的患者。收集的数据包括:人口统计学、药物使用、哮喘控制、哮喘相关认知和行为。使用描述性分析总结数据。
375 名参与者完成了调查,其中 73.9%为高 SABA 用户。在这 375 名参与者中,90.4%报告其哮喘症状得到控制或有所控制,56.0%认为其哮喘不严重。然而,根据 GINA 定义的标准,仅有 17.6%的人控制了哮喘。高 SABA 用户往往对哮喘更加焦虑,并担心其未来的影响(50.5% vs. 28.6%, < 0.001)。高 SABA 用户更有可能同意以下陈述,即哮喘影响日常生活活动(46.6% vs. 16.3%, < 0.001);对哮喘具有社会意识,并更有可能感到尴尬携带(21.3% vs 9.2%, = 0.007)和使用(29.2% vs 18.4%, = 0.036)他们的哮喘吸入器。
本研究揭示了未控制哮喘的程度,并发现了一群焦虑和具有社会意识的 OTC SABA 用户。需要更好地了解患者的认知及其与高 SABA 使用的关系,以确保制定和实施有针对性的教育干预措施。